Nektar guides 2026 R&D $200–$250M for ResPeg after beating Q4 2025 estimates with EPS -$1.78 and revenue $21.8M
- Q4 2025 non-GAAP EPS of -$1.78 declined 496% year over year.
- Q4 2025 revenue was $21.8M, down 25% year over year despite topping expectations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.